DANVERS, Mass., and SAN DIEGO (February 2, 2024) –
Beckman Coulter Genomics Inc., and Genpathway, Inc., today
announced a strategic partnership to offer customers whole-genome
chromatin immunoprecipitation sequencing (ChIP-Seq) services.
The alliance provides researchers investigating gene regulation and
genetic pathways a single, inclusive source for services supporting
genome-wide studies of transcription factor binding, gene
transcription and epigenetic events.
"Partnering with leading-edge innovators to respond to the
dynamic research needs of scientists worldwide is fundamental to
our goals as an essential genomic services provider," said
Elizabeth Nickerson, global business line leader of DNA sequencing
services at Beckman Coulter Genomics. "This alliance with
Genpathway strategically leverages both companies’ core
competencies and expertise to supplement our DNA sequencing
services with the highest-quality, most reliable ChIP-Seq
capabilities available."
ChIP-Seq combines the sophistication of chromatin
immunoprecipitation with the power of ultra high-throughput next
generation DNA sequencing to enable the study of complex
interactions between proteins and nucleic acids. Mapping
protein-DNA complexes in vivo on a genome-wide scale with ChIP-Seq
builds a picture of the intricate network of interactions that
regulate genes and genetic pathways in a sample. Comparing
ChIP-Seq results from different conditions – diseased versus
normal cells, for example – can reveal distinguishing
patterns of genetic regulation that may be biologically
significant.
"We are pleased that Beckman Coulter Genomics has selected
Genpathway as its partner to accommodate the unprecedented
requirement for ChIP-based technologies to advance studies of
biological processes and disease states," said Patrick Mallon, CEO
of Genpathway. "This dynamic new alliance is a natural fit,
coupling Beckman Coulter Genomics’ sequencing and marketing
capabilities with Genpathway’s ChIP experience to offer the
global research community an expert source of ChIP sequencing data
and analysis."
Beckman Coulter Genomics services include Sanger and next
generation DNA sequencing, gene expression profiling, genotyping
and biologics testing. The collaboration with Genpathway
further expands the company’s extensive DNA sequencing
applications portfolio, which is available to clients
worldwide. The start-to-finish ChIP-Seq services will include
ChIP experimental design and consultation, antibody qualification,
performance of ChIP assays with post-ChIP QC, next generation
sequencing and comprehensive data analysis.
About Beckman Coulter Genomics
Beckman Coulter Genomics, headquartered in Danvers, Massachusetts,
is a leading provider of genomic services and nucleic acid
purification products, serving life-science researchers and the
pharmaceutical industry throughout the world. The company, a
wholly owned subsidiary of Beckman Coulter, was created by
combining Beckman Coulter’s Agencourt Bioscience with the
newly acquired Cogenics. By providing technical expertise,
combined with personalized service, Beckman Coulter Genomics
delivers the highest quality data, robust analyses and innovative
thinking. For more information, visit www.beckmangenomics.com.
About Genpathway
Genpathway, Inc. is an early-stage pharmacogenomics company that
provides specialized drug and biomarker discovery and development
services that aid in predicting drug responses, enabling
personalized treatments. The company applies its proprietary
chromatin and methylated DNA immunoprecipitation (ChIP) technology
to understand gene regulation and genetic pathways by studying
transcription factor binding, gene transcription, and epigenetic
events such as DNA methylation and histone modifications. For
more information, visit www.genpathway.com.
Beckman Coulter and the stylized logo are registered trademarks
of Beckman Coulter, Inc
SOURCE